Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword
This article was originally published in The Pink Sheet Daily
Executive Summary
Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.